Search results
Results From The WOW.Com Content Network
Ankylosing spondylitis (AS) is a type of arthritis from the disease spectrum of axial spondyloarthritis. [5] It is characterized by long-term inflammation of the joints of the spine, typically where the spine joins the pelvis. [2] With AS, eye and bowel problems—as well as back pain—may occur. [2]
Since the disease ankylosing spondylitis was still defined by the Modified New York criteria of 1984, there was the need to find a new disease term that would also include the less severe forms or early onset of ankylosing spondylitis. This expression was found in the umbrella term axial spondyloarthritis.
Among the genetic factors that may influence ankylosing spondylitis, the HLA-B27 gene accounts for about thirty percent of the overall genetic risk, per the National Library of Medicine. The ...
Ankylosing spondylitis is a type of arthritis in which there is long-term inflammation of the joints of the spine. [2] Other forms of arthritis may sometimes also lead to ankylosis, including rheumatoid arthritis and reactive arthritis; Osteoarthritis usually confers osteophyte formation, which may eventually fuse across joints. Osteoarthritis ...
Ankylosing spondylitis (AS) is a form of arthritis that primarily affects the spine, although other joints can become involved. It causes inflammation of the spinal joints (vertebrae) that can lead to severe, chronic pain and discomfort.
Ankylosing spondylitis is a genetic disease with identifiable marks, tends to start showing signs in adolescence or young adulthood, is more likely to affect the lumbar spine, and affects organs. DISH has no indication of a genetic link, is primarily thoracic and does not affect organs other than the lungs, and only indirectly due to the fusion ...
The BASDAI or Bath Ankylosing Spondylitis Disease Activity Index is a validated diagnostic test which allows a physician, usually a rheumatologist, to determine the effectiveness of a current drug therapy, or the need to institute a new drug therapy for the treatment of Ankylosing spondylitis (AS).
Patients with type 2 diabetes taking GLP-1 treatments, which include Ozempic, have a lower chance of developing 10 types of obesity-related cancers than those taking insulin and other diabetes ...